Metastasis—the process by which cancer cells disseminate from the primary tumor to distant organs—is the leading cause of cancer-related deaths. Unraveling the molecular underpinnings that promote this lethal progression is paramount. Twist1, a well-known EMT (epithelial-mesenchymal transition) transcription factor, has long been implicated in facilitating cancer cell plasticity and invasiveness. However, until now, the precise post-translational modifications maintaining its stability remained elusive.

The research team meticulously demonstrated that UCHL1, a deubiquitinating enzyme, exerts pivotal control over Twist1 by removing ubiquitin chains linked through lysine residues K11 and K63. Normally, ubiquitination tags proteins for degradation via the proteasome, but the removal of these specific ubiquitin linkages by UCHL1 prevents Twist1 degradation. This stabilization allows Twist1 to persist and actively drive the metastatic cascade.

Deubiquitination is an emerging field with vast implications in oncology, as it directly impacts protein half-life and function. UCHL1’s role here is particularly intriguing since it favors the cleavage of K11- and K63-linked ubiquitin chains, not the canonical K48 linkages typically associated with protein breakdown. This selective activity suggests a nuanced regulatory layer that cancer cells exploit for survival and dissemination.

By using NSCLC cell lines and patient-derived tumor samples, the study compellingly correlates elevated UCHL1 expression with increased Twist1 protein levels and poorer clinical outcomes. The mechanistic experiments revealed that silencing UCHL1 notably reduces Twist1 half-life, inhibits EMT marker expression, and profoundly suppresses cellular migration and invasion capabilities in vitro. These findings substantiate UCHL1 as a key driver of metastatic phenotypes.

On a molecular scale, the team employed cutting-edge ubiquitination assays and mass spectrometry to identify the specific ubiquitin linkages and their removal by UCHL1. Insights from these assays illuminate the enzyme’s substrate specificity, a critical aspect in designing future inhibitors that could selectively target this deubiquitinase without eliciting widespread off-target effects.

From a therapeutic standpoint, the identification of UCHL1 as a modulator of Twist1 stability opens compelling avenues. Deubiquitinase inhibitors, though still an emerging class of drugs, hold promise in dismantling the metastatic machinery at a post-translational level. By destabilizing Twist1, such inhibitors could thwart the EMT process and consequently, impede metastatic colonization.

Moreover, this research accentuates the importance of complex post-translational modifications (PTMs) in cancer progression. Historically overshadowed by genetic mutations and transcriptional changes, PTMs like ubiquitination/deubiquitination are now recognized as dynamic regulators of protein function, localization, and turnover—factors that decisively influence cellular fate during oncogenesis.

The study further delves into the interplay between K11 and K63 ubiquitin chains. While K63-linked chains have recognized roles in signaling and protein trafficking, K11-linked chains are traditionally involved in cell cycle regulation. Their combined removal from Twist1 suggests a multifaceted modulation of its activity and degradation dynamics, potentially integrating diverse cellular signals that facilitate metastasis.

Importantly, the findings underscore a previously underappreciated axis in NSCLC’s metastatic program centered around UCHL1 and Twist1. This axis represents a vulnerability that, if clinically targeted, might dramatically improve patient prognoses by diminishing the metastatic burden, which currently limits survival despite advances in targeted and immunotherapies.

In addition to translational applications, this work prompts a reevaluation of UCHL1’s role in cancer biology. Historically linked to neurological disorders and proteostasis, its oncogenic potential manifests distinctly in lung cancer metastasis—a paradigm shift that may inspire broader investigations across other tumor types exhibiting elevated UCHL1 levels.

The researchers also postulate that UCHL1-mediated deubiquitination could influence other EMT-related transcription factors or metastatic regulators, suggesting a more expansive regulatory network that coordinates tumor cell plasticity. Future research may uncover additional substrates and pathways modulated by this enzyme, further enriching the therapeutic landscape.

By illuminating the delicate balance between ubiquitination and deubiquitination in the metastatic cascade, this study propels a new frontier of cancer research that integrates chemical biology, molecular oncology, and clinical relevance. Targeting such post-translational regulatory nodes could revolutionize strategies for combating metastatic disease.

In conclusion, this seminal work unravels a novel molecular mechanism where UCHL1 stabilizes Twist1 through K11/K63-linked deubiquitination, driving the aggressive metastatic behavior of non-small cell lung cancer. The therapeutic implications are profound, with a compelling rationale for developing deubiquitinase inhibitors that disable metastatic programs at their molecular core, holding renewed hope for patients afflicted by this formidable disease.

Subject of Research: Molecular mechanisms driving metastasis in non-small cell lung cancer through UCHL1-mediated deubiquitination of Twist1

Article Title: UCHL1 stabilizes Twist1 via K11/K63-linked deubiquitination to drive tumor metastasis in non-small cell lung cancer

Article References:

Feng, Q., Hu, Q., Huang, Q. et al. UCHL1 stabilizes Twist1 via K11/K63-linked deubiquitination to drive tumor metastasis in non-small cell lung cancer.
Cell Death Discov. (2025). https://doi.org/10.1038/s41420-025-02925-8

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02925-8

Glioblastoma is characterized by its remarkable heterogeneity, aggressive invasion into surrounding brain tissue, and an uncanny ability to evade existing therapies, leading to dismal patient prognoses. Central to this malignancy is a subpopulation of cancer stem-like cells that drive tumor recurrence and therapeutic resistance. SOX9, a transcription factor well-known for its roles in development and stem cell biology, has emerged as a key player in maintaining this stem-like state. However, the post-translational dynamics that govern SOX9 stability within glioblastoma cells were poorly understood until now.

The study elucidates how USP18, a ubiquitin-specific protease, functions as a deubiquitinase for SOX9, effectively rescuing it from proteasomal degradation. Ubiquitination is a cellular process that tags proteins for destruction; in contrast, deubiquitination removes these tags, rescuing proteins from being broken down. By stabilizing SOX9, USP18 ensures the persistence of its oncogenic functions, such as promoting self-renewal, proliferative capacity, and survival of glioblastoma stem-like cells. This molecular axis thus represents a critical node in the maintenance of glioblastoma’s aggressive phenotype.

The researchers employed a combination of biochemical analyses, genetic manipulation, and in vitro and in vivo models to dissect the role of USP18 in glioblastoma. They demonstrated that knocking down USP18 leads to increased ubiquitination and subsequent degradation of SOX9, thereby impairing the stemness and proliferation of glioblastoma cells. Conversely, USP18 overexpression stabilized SOX9 and enhanced malignant properties, confirming the enzyme’s oncogenic influence. These manipulations directly impacted tumor growth rates and invasion capabilities in animal models, underscoring the clinical relevance of the findings.

Mechanistically, the deubiquitination activity of USP18 targets specific lysine residues on SOX9, preventing proteasome-mediated destruction. This direct interaction was confirmed through co-immunoprecipitation and ubiquitination assays, pinpointing USP18 as an indispensable regulator of SOX9 protein homeostasis. The stabilization of SOX9 consequently sustains the gene expression programs vital for glioblastoma stemness, including the regulation of pathways involved in cell cycle progression, survival, and DNA damage response.

Beyond the molecular interaction, the study sheds light on the broader oncogenic landscape of glioblastoma. The USP18-SOX9 axis represents a critical link connecting post-translational modification machinery to transcriptional control mechanisms sustaining tumor aggressiveness. Given the notorious difficulty in targeting transcription factors like SOX9 directly, USP18 emerges as an attractive druggable target. Inhibiting USP18’s enzymatic activity could destabilize SOX9, thereby attenuating the tumor’s stem cell-like properties and sensitizing glioblastoma cells to chemotherapy and radiotherapy.

Importantly, USP18 has been previously implicated in immune regulation and interferon signaling, indicating potential pleiotropic effects of targeting this protease. This dual functionality necessitates a nuanced therapeutic approach, possibly involving USP18 inhibitors tailored to selectively disrupt its interaction with SOX9 without compromising essential immune functions. The study’s insights into the specificity of USP18’s substrate interactions provide a valuable foundation for designing such targeted inhibitors.

In addition to therapeutic implications, this discovery advances the fundamental biology of glioblastoma by highlighting how protein stability regulation intricately controls cancer stem cell phenotypes. The ability of USP18 to modulate SOX9 protein levels post-translationally exemplifies the complex regulatory networks cancer cells leverage to maintain their malignant features. This underscores an emerging theme in oncology where deubiquitinases play central roles in sustaining oncogenic signaling pathways.

Further exploration of the USP18-SOX9 axis revealed that this interaction is dynamically regulated in response to environmental stressors and therapeutic pressures. For instance, hypoxic conditions within the tumor microenvironment and exposure to genotoxic agents appear to enhance USP18 expression, thereby reinforcing SOX9 stabilization and contributing to therapy resistance. Understanding these adaptive responses could inform the timing and combination of USP18-targeted therapies to maximize clinical efficacy.

Moreover, the spatial and temporal expression patterns of USP18 and SOX9 were characterized in glioblastoma patient samples, correlating high levels of both proteins with poorer clinical outcomes. This clinical correlation strengthens the translational relevance and positions USP18-SOX9 as a prognostic biomarker axis. Consequently, assessing USP18 and SOX9 expression could guide patient stratification and personalized treatment regimens designed to inhibit this malignant circuitry.

This landmark study expands the therapeutic horizon for glioblastoma by highlighting a novel vulnerability in the cancer’s molecular armor. Targeting the USP18-mediated stabilization of SOX9 presents a compelling strategy to dismantle the self-renewing tumor cell compartment that drives recurrence and resistance. As glioblastoma continues to defy conventional therapies, such innovative molecular insights offer a beacon of hope for developing more effective treatments and improving patient survival.

Future research directions will focus on developing small-molecule inhibitors or biologics that disrupt USP18’s catalytic function or its binding interface with SOX9. Additionally, integrating USP18 targeting with existing modalities, such as immune checkpoint blockade and radiotherapy, may produce synergistic effects. Combining these approaches could help overcome the multifaceted defense mechanisms glioblastoma employs, ushering in a new era of precision oncology tailored to the disease’s molecular underpinnings.

In conclusion, the study’s identification of USP18 as a master regulator of SOX9 stability and glioblastoma stemness represents a profound leap forward in understanding the disease’s biology. It exemplifies how deciphering post-translational modifications can reveal hidden drivers of tumor aggressiveness and resistance. With USP18’s enzymatic activity acting as a linchpin in maintaining the malignant phenotype, targeted interventions disrupting this axis hold transformative potential for combating glioblastoma’s devastating impact.

Subject of Research: Regulation of glioblastoma stemness and malignancy via USP18-mediated deubiquitination and stabilization of SOX9.

Article Title: USP18 deubiquitinates and stabilizes SOX9 to promote the stemness and malignant progression of glioblastoma.

Article References:
Liu, Z., Yu, K., Chen, K. et al. USP18 deubiquitinates and stabilizes SOX9 to promote the stemness and malignant progression of glioblastoma. Cell Death Discov. 11, 237 (2025). https://doi.org/10.1038/s41420-025-02522-9

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02522-9